Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1 1

Status

Completed 4

Sponsor Class

INDUSTRY 4

Study Type

Interventional 4

Sponsor

Cancer Type

Gastrointestinal 2Thoracic 1Gynecologic 1

Conditions

Stomach Neoplasms 2Esophageal Neoplasms 2Ovarian Neoplasms 1Lung Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Adenocarcinoma Of Esophagus 1Adenocarcinoma 1

Interventions

Cyclophosphamide 1492Cisplatin 1414Paclitaxel 1317Radiotherapy 1261Carboplatin 1250Gemcitabine 1215Docetaxel 1109Bevacizumab 1030Fluorouracil 894Doxorubicin 792Dexamethasone 748Rituximab 719Capecitabine 716Oxaliplatin 700pembrolizumab 680Etoposide 678Irinotecan 634Filgrastim 621Cytarabine 586Leucovorin 579Nivolumab 558Vincristine 515Prednisone 475Cetuximab 465Bortezomib 459Erlotinib Hydrochloride 456Trastuzumab 447Methotrexate 438Lenalidomide 427Pemetrexed 420

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Completed × Interventional × matuzumab × Clear all
NCT00215644 2018-11-02

MATRIX EG

Merck KGaA, Darmstadt, Germany

Phase 2 Completed
72 enrolled 7 charts
Gastrointestinal

Adenocarcinoma, Esophageal Neoplasms, Stomach Neoplasms

NCT00111839 2018-04-06

Effects of Matuzumab in Combination With Pemetrexed for the Treatment of Advanced Lung Cancer

EMD Serono

Phase 2 Completed
150 enrolled 10 charts
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT00073541 2017-01-20

A Study of the Safety and Effects of EMD 72000 in Subjects With Recurrent Ovarian Cancer

EMD Serono

Phase 2 Completed
38 enrolled
Gynecologic

Ovarian Neoplasms

NCT00113581 2014-02-19

Safety Study of EMD 72000 in Combination With ECX (Epirubicin, Cisplatin and Capecitabine) in Oesophagogastric Cancer

Merck KGaA, Darmstadt, Germany

Phase 1 Completed
26 enrolled
Gastrointestinal

Adenocarcinoma Of Esophagus, Esophageal Neoplasms, Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡